Publicação

Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice

Ver documento

Detalhes bibliográficos
Resumo:Perampanel (PER) is a potent third-generation antiepileptic drug only available for oral administration. Additionally, PER has shown potential in managing epilepsy comorbidities such as anxiety. Previously, we demonstrated that the intranasal (IN) administration of PER, loaded in a self-microemulsifying drug delivery system (SMEDDS), improved brain-targeting and exposure in mice. Herein, we investigated PER brain biodistribution, its anticonvulsant and anxiolytic effects, and its potential olfactory and neuromotor toxicity after IN administration to mice (1 mg/kg). PER showed a rostral-caudal brain biodistribution pattern when administered intranasally. At short times post-nasal dosing, high PER concentrations were found in olfactory bulbs (olfactory bulbs/plasma ratios of 1.266 ± 0.183 and 0.181 ± 0.027 after IN and intravenous administrations, respectively), suggesting that a fraction of the drug directly reaches brain through the olfactory pathway. In the maximal electroshock seizure test, IN PER protected 60% of mice against seizure development, a substantially higher value than the 20% protected after receiving oral PER. PER also demonstrated anxiolytic effects in open field and elevated plus maze tests. Buried food-seeking test showed no signs of olfactory toxicity. Neuromotor impairment was found in rotarod and open field tests at the times of PER maximum concentrations after IN and oral administrations. Nevertheless, neuromotor performance was improved after repeated administrations. Compared with IN vehicle, PER IN administration decreased brain levels of L-glutamate (0.91 ± 0.13 mg/mL vs 0.64 ± 0.12 mg/mL) and nitric oxide (100 ± 15.62% vs 56.62 ± 4.95%), without interfering in GABA levels. Altogether, these results suggest that the IN PER delivery through the developed SMEDDS can be a safe and promising alternative to the oral treatment, which supports the design of clinical studies to evaluate the IN PER delivery to treat epilepsy and neurological-related conditions as anxiety.
Autores principais:Meirinho, Sara
Outros Autores:Rodrigues, Márcio; Santos, Adriana; Falcão, Amílcar; Alves, Gilberto
Assunto:Perampanel Intranasal Brain biodistribution Anticonvulsant Anxiolytic
Ano:2023
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Universidade Politécnica da Guarda
Idioma:inglês
Origem:Repositório Científico da Universidade Politécnica da Guarda
_version_ 1880131246244233216
author Meirinho, Sara
author2 Rodrigues, Márcio
Santos, Adriana
Falcão, Amílcar
Alves, Gilberto
author2_role author
author
author
author
author_facet Meirinho, Sara
Rodrigues, Márcio
Santos, Adriana
Falcão, Amílcar
Alves, Gilberto
author_role author
contributor_name_str_mv Repositório Científico da Universidade Politécnica da Guarda
country_str PT
creators_json_txt [{\"Person.name\":\"Meirinho, Sara\"},{\"Person.name\":\"Rodrigues, Márcio\"},{\"Person.name\":\"Santos, Adriana\"},{\"Person.name\":\"Falcão, Amílcar\"},{\"Person.name\":\"Alves, Gilberto\"}]
datacite.contributors.contributor.contributorName.fl_str_mv Repositório Científico da Universidade Politécnica da Guarda
datacite.creators.creator.creatorName.fl_str_mv Meirinho, Sara
Rodrigues, Márcio
Santos, Adriana
Falcão, Amílcar
Alves, Gilberto
datacite.date.Accepted.fl_str_mv 2023-11-02T00:00:00Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv Perampanel
Intranasal
Brain biodistribution
Anticonvulsant
Anxiolytic
datacite.titles.title.fl_str_mv Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice
dc.contributor.none.fl_str_mv Repositório Científico da Universidade Politécnica da Guarda
dc.creator.none.fl_str_mv Meirinho, Sara
Rodrigues, Márcio
Santos, Adriana
Falcão, Amílcar
Alves, Gilberto
dc.date.Accepted.fl_str_mv 2023-11-02T00:00:00Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv https://hdl.handle.net/10314/8964
dc.language.none.fl_str_mv eng
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.subject.none.fl_str_mv Perampanel
Intranasal
Brain biodistribution
Anticonvulsant
Anxiolytic
dc.title.fl_str_mv Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
description Perampanel (PER) is a potent third-generation antiepileptic drug only available for oral administration. Additionally, PER has shown potential in managing epilepsy comorbidities such as anxiety. Previously, we demonstrated that the intranasal (IN) administration of PER, loaded in a self-microemulsifying drug delivery system (SMEDDS), improved brain-targeting and exposure in mice. Herein, we investigated PER brain biodistribution, its anticonvulsant and anxiolytic effects, and its potential olfactory and neuromotor toxicity after IN administration to mice (1 mg/kg). PER showed a rostral-caudal brain biodistribution pattern when administered intranasally. At short times post-nasal dosing, high PER concentrations were found in olfactory bulbs (olfactory bulbs/plasma ratios of 1.266 ± 0.183 and 0.181 ± 0.027 after IN and intravenous administrations, respectively), suggesting that a fraction of the drug directly reaches brain through the olfactory pathway. In the maximal electroshock seizure test, IN PER protected 60% of mice against seizure development, a substantially higher value than the 20% protected after receiving oral PER. PER also demonstrated anxiolytic effects in open field and elevated plus maze tests. Buried food-seeking test showed no signs of olfactory toxicity. Neuromotor impairment was found in rotarod and open field tests at the times of PER maximum concentrations after IN and oral administrations. Nevertheless, neuromotor performance was improved after repeated administrations. Compared with IN vehicle, PER IN administration decreased brain levels of L-glutamate (0.91 ± 0.13 mg/mL vs 0.64 ± 0.12 mg/mL) and nitric oxide (100 ± 15.62% vs 56.62 ± 4.95%), without interfering in GABA levels. Altogether, these results suggest that the IN PER delivery through the developed SMEDDS can be a safe and promising alternative to the oral treatment, which supports the design of clinical studies to evaluate the IN PER delivery to treat epilepsy and neurological-related conditions as anxiety.
dirty 0
eu_rights_str_mv openAccess
format article
id ripg_b6f67b59129cf59f90dbbc4ee0f27dff
identifier.other.fl_str_mv https://hdl.handle.net/10314/8964
inst_facet_str urn:organizationAcronym:upg{{{_:::_}}}Universidade Politécnica da Guarda
instacron_str upg
institution Universidade Politécnica da Guarda
instname_str Universidade Politécnica da Guarda
language eng
network_acronym_str ripg
network_name_str Repositório Científico da Universidade Politécnica da Guarda
oai_identifier_str oai:repositorio.ipg.pt:10314/8964
organization_str_mv urn:organizationAcronym:upg
person_str_mv Meirinho, Sara
Rodrigues, Márcio
Santos, Adriana
Falcão, Amílcar
Alves, Gilberto
publishDate 2023
repo_facet_str urn:repositoryAcronym:ripg{{{_:::_}}}Repositório Científico da Universidade Politécnica da Guarda
reponame_str Repositório Científico da Universidade Politécnica da Guarda
repository_id_str urn:repositoryAcronym:ripg
service_str_mv urn:repositoryAcronym:ripg
spelling engPerampanel (PER) is a potent third-generation antiepileptic drug only available for oral administration. Additionally, PER has shown potential in managing epilepsy comorbidities such as anxiety. Previously, we demonstrated that the intranasal (IN) administration of PER, loaded in a self-microemulsifying drug delivery system (SMEDDS), improved brain-targeting and exposure in mice. Herein, we investigated PER brain biodistribution, its anticonvulsant and anxiolytic effects, and its potential olfactory and neuromotor toxicity after IN administration to mice (1 mg/kg). PER showed a rostral-caudal brain biodistribution pattern when administered intranasally. At short times post-nasal dosing, high PER concentrations were found in olfactory bulbs (olfactory bulbs/plasma ratios of 1.266 ± 0.183 and 0.181 ± 0.027 after IN and intravenous administrations, respectively), suggesting that a fraction of the drug directly reaches brain through the olfactory pathway. In the maximal electroshock seizure test, IN PER protected 60% of mice against seizure development, a substantially higher value than the 20% protected after receiving oral PER. PER also demonstrated anxiolytic effects in open field and elevated plus maze tests. Buried food-seeking test showed no signs of olfactory toxicity. Neuromotor impairment was found in rotarod and open field tests at the times of PER maximum concentrations after IN and oral administrations. Nevertheless, neuromotor performance was improved after repeated administrations. Compared with IN vehicle, PER IN administration decreased brain levels of L-glutamate (0.91 ± 0.13 mg/mL vs 0.64 ± 0.12 mg/mL) and nitric oxide (100 ± 15.62% vs 56.62 ± 4.95%), without interfering in GABA levels. Altogether, these results suggest that the IN PER delivery through the developed SMEDDS can be a safe and promising alternative to the oral treatment, which supports the design of clinical studies to evaluate the IN PER delivery to treat epilepsy and neurological-related conditions as anxiety.application/pdfNose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in miceMeirinho, SaraRodrigues, MárcioSantos, AdrianaFalcão, AmílcarAlves, GilbertoHostingInstitutionOrganizationalRepositório Científico da Universidade Politécnica da Guardae-mailmailto:no-reply+repositorio@ipg.ptno-reply+repositorio@ipg.ptISSNIsPartOf0378-5173URNIsPartOf6422023-11-022023-11-02T00:00:00ZHANDLEhttps://hdl.handle.net/10314/8964http://purl.org/coar/access_right/c_abf2open accessPerampanelIntranasalBrain biodistributionAnticonvulsantAnxiolytic3273439 bytesliteraturehttp://purl.org/coar/resource_type/c_6501journal articlehttp://purl.org/coar/access_right/c_abf2application/pdfhttps://repositorio.ipg.pt/bitstreams/b32b3e05-da51-478b-b8fa-83dd2781ae9c/download
spellingShingle Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice
Meirinho, Sara
Perampanel
Intranasal
Brain biodistribution
Anticonvulsant
Anxiolytic
status SINGLETON
subject.fl_str_mv Perampanel
Intranasal
Brain biodistribution
Anticonvulsant
Anxiolytic
title Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice
title_full Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice
title_fullStr Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice
title_full_unstemmed Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice
title_short Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice
title_sort Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice
topic Perampanel
Intranasal
Brain biodistribution
Anticonvulsant
Anxiolytic
topic_facet Perampanel
Intranasal
Brain biodistribution
Anticonvulsant
Anxiolytic
url https://hdl.handle.net/10314/8964
visible 1

Atividades financiadas

Não foram encontrados projetos financiados.